| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | setmelanotide (IMCIVREE) Acquired hypothalamic obesity, participants with prior bariatric surgery | Phase 3 | — | Peptides | Endocrine System | ||
Phase 3 data readout example | setmelanotide (IMCIVREE) Acquired hypothalamic obesity, participants with prior bariatric surgery | Phase 3 | — | Peptides | Endocrine System | ||
Phase 3 data readout example | setmelanotide (IMCIVREE) Acquired hypothalamic obesity, participants with prior bariatric surgery | Phase 3 | — | Peptides | Endocrine System |
Recent Updates
Recently added Catalysts
Rhythm Pharmaceuticals, Inc.$88.38
+1.36 (+1.55%)
B 65Pipeline Score Fair Value Pharma · Commercial
Market Cap
6.02 B
EPS
-3.14
P/E Ratio
-
Value Trade
35.22 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
60.11 M
R&D Expenses
41.73 M
Operating CF
-44.19 M
Total Assets
442.32 M
Total Liabilities
204.70 M
Equity
122.91 M
D/E Ratio
12,345
-4.74 %
Week
2.83 %
1 Month
-14.68 %
3 Month
-12.92 %
6 Month
305.73 %
5 Year
278.46 %
All Time
Cash Data
Cash Position
340.63 M
Monthly Burn
14.73 M
Runway
21.9 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
554.45 K
52 Week Range
58.71 - 122.20
% held by Insiders
3.17 %
% held by Institutions
105.76 %
Enterprise Value
5.91 B
Total Shares
68.53 M
Short %
11.91 %
Float Shares
61.13 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
B65
Pipeline Score $4.5B
Pipeline ValueFair Value
Valuation Signal8
Drugs Scored0.8x
rNPV / MCap Top 91%
Small Cap (rank 82 of 905)
Percentile RankRhythm Pharmaceuticals, Inc. holds a solid B-grade pipeline (65/100), with $7.2B risk-adjusted pipeline value, led by Setmelanotide in Genetic Obesity (Phase 2), across $121B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Setmelanotide Small molecule | Obesity | Phase 3 | NCT05093634 | 59% | $3.3B | ACTIVE NOT_RECRUITING | 296 | STALLED | B (72) | Dec 31, 2026 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
setmelanotide | acquired hypothalamic obesity | Phase 3 | 2025-06-25 | |||
setmelanotide | acquired hypothalamic obesity | Phase 3 | 2025-06-25 | |||
setmelanotide | acquired hypothalamic obesity | Phase 3 | 2025-06-25 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RYTM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
RYTM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RYTM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RYTM
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
RYTM Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
RYTM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-12-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Rhythm Pharmaceuticals, Inc. (RYTM) News & Alerts
-
Demo Biotech Announces Positive Phase 3 Results
Competitive Position
How RYTM ranks across every disease it competes in| Indication | Rank | Phase | Best Drug | Top 3 Competitors | Market $B | LoA | Position |
|---|---|---|---|---|---|---|---|
| Congenital Disorders | #1 of 2 | Setmelanotide | ZBH ·dev | $15.2B | 0.9 | ||
| Pituitary Disorders | #1 of 2 | Setmelanotide | NVO | $0.44B | 0.98 | ||
| Genetic Disorders | #2 of 8 | Part C: RM-718 + Part D: RM-718 | TAK SABS REGN | $7.95B | 0.99 | ||
| Obesity | #4 of 33 | Setmelanotide | LLY AMGN NVO | $22.52B | 0.96 | ||
| Cardiomyopathy | #11 of 13 | Tideglusib | BMY CYTK LXRX | $1.5B | 0 | ||
| Rare Genetic Disorders | #24 of 61 | Setmelanotide | BMRN ASND NVS | — | 0.93 |